Topic:

April 2024

Lupus Canada is pleased to share that Health Canada has approved Evusheld for pre-exposure prophylaxis of COVID-19 in immune-compromised individuals.

Evusheld is now approved for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 and have not had recent known contact with someone infected with COVID-19, and:

  • who are immune compromised and unlikely to mount an adequate immune response to COVID‐19 vaccination; or,
  • for whom COVID-19 vaccination is not recommended

For more information please visit EVUSHELD™ RECEIVES HEALTH CANADA APPROVAL FOR PRE-EXPOSURE PROPHYLAXIS (PREVENTION) OF COVID-19 IN IMMUNE-COMPROMISED INDIVIDUALS (newswire.ca)

To review the Health Statement please visit:

https://www.canada.ca/en/health-canada/news/2022/04/health-canada-authorizes-evusheld-for-the-prevention-of-covid-19-in-immune-compromised-adults-and-children.html

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Anifrolumab (Saphnelo) listed in SK

Read

Belimumab (Benlysta) listed in AB, NL & NIHB

Read

Belimumab (Benlysta) listed in ON

Read